• PR-619 for DUB Inhibition in Cell Assays

  2026-09-16

  PR-619 is a reversible, cell-permeable deubiquitylating enzymes inhibitor for mapping ubiquitin-dependent proteostasis, autophagy, cancer phenotypes, and neurodegenerative mechanisms. This workflow distinguishes upstream DUB inhibition from direct proteasome blockade and shows how to connect ubiquitin readouts with the oncogenic signaling findings reported in HPV-positive HeLa cells.

• SB203580: Selective p38 MAPK Inhibitor

  2026-09-16

  SB203580 is an ATP-competitive p38 MAPK inhibitor used to interrogate stress, inflammatory, and pain-related signaling. Its reported p38 MAPK IC50 is 0.3–0.5 μM in supplier-reported assays, while the 2024 orofacial pain study supports ROS–p38 signaling as a testable pathway context.

• HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus

  2026-09-15

  The HyperScribe™ T7 High Yield Cy3 RNA Labeling Kit Plus supports in vitro transcription of randomly Cy3-modified RNA probes for fluorescence-based detection. It is intended for research applications such as in situ hybridization and Northern blot hybridization, and should not be used for diagnostic, clinical, therapeutic, or medical workflows.

• 3D Osteocyte Networks Under Pulsatile Flow

  2026-09-15

  Merife and colleagues developed a transparent three-chamber microfluidic platform for studying three-dimensional MLO-Y4 osteocyte networks exposed to pulsatile unidirectional fluid flow stimuli. The model links defined mechanical stimulation with real-time calcium signaling, long-term osteocyte phenotype, and Cx43-dependent network communication.

• 5X Protein Loading Buffer (Reducing): Protocol Guide

  2026-09-14

  5X Protein Loading Buffer (Reducing), SKU K1164, supports denaturing and reducing protein sample preparation before SDS-PAGE electrophoresis by combining SDS, a sulfhydryl reducing agent, buffer salts, and bromophenol blue. It is intended for molecular-weight-based separation under reducing conditions and should not be used when native protein structure, protein complexes, or non-reducing disulfide states must be preserved.

• Standardized Whole-Blood Stimulation in Immunometabolism

  2026-09-14

  Zhao and colleagues present a standardized whole-blood stimulation protocol for measuring how metabolic interventions reshape human immune responses. The approach combines physiologically relevant blood-based stimulation, defined immune and microbial triggers, metabolic pathway modulation, and cytokine quantification to support reproducible cohort studies and mechanistic immunometabolism research.

• Birinapant (TL32711) for Apoptosis Workflows

  2026-09-13

  Birinapant (TL32711) converts IAP biology into a practical tool for testing caspase-8 activation, TNF-mediated NF-κB inhibition, and TRAIL potency enhancement. This workflow-focused guide connects its SMAC-mimetic mechanism with MDM1–p53 evidence in colorectal cancer, while clearly separating validated findings from recommended pilot conditions.

• Etomoxir: A Decision Framework for Immunometabolism

  2026-09-12

  Etomoxir and R-(+)-Etomoxir are powerful tools for probing fatty acid oxidation and immune metabolism. This article presents an assay-centered framework that separates CPT-1 biology from concentration-dependent confounding and connects whole-blood experiments with carefully bounded neuroinflammation research.

• Viral RIPK3 Degradation and Proteasome-Controlled Inflammati

  2026-09-11

  Liu et al. identified a family of orthopoxvirus proteins, termed viral inducers of RIPK3 degradation, that recruit host SCF machinery to ubiquitinate and eliminate RIPK3, suppressing necroptosis. The study links this proteasome-dependent immune-evasion mechanism to viral replication, inflammation, mortality, and pathogen–host evolution, while providing a framework for dissecting degradation-dependent control of inflammatory cell death.

• Relative and Fractional Viability in Cancer Drug Testing

  2026-09-11

  Hannah R. Schwartz’s 2022 dissertation distinguishes relative viability from fractional viability, showing that these measures capture different combinations of proliferative inhibition and cell death. The framework supports better assay design and more cautious interpretation of drug-response data in cancer research.

• FAST Nanoparticles for Food-Grade Nutraceutical Delivery

  2026-09-10

  The 2026 reference study evaluates Facilitated Self-Assembling Technology (FAST) as a surfactant-free, food-grade route for producing stable nanoparticles from poorly soluble nutraceuticals. Its results support FAST as a promising formulation platform, while also indicating that product-specific bioavailability, composition, and regulatory studies remain necessary before broad translation.

• MLN4924: From Neddylation to Combination Strategy

  2026-09-10

  MLN4924 is more than a potent NEDD8-activating enzyme inhibitor: it is a mechanistic probe for connecting neddylation pathway inhibition with protein turnover, cell-cycle stress, and rational combination therapy. Evidence from head and neck squamous cell carcinoma research illustrates how pathway-level pharmacology can guide translational study design.

• Clasto-Lactacystin β-lactone Proteasome Workflows

  2026-09-09

  Use Clasto-Lactacystin β-lactone as a causal probe of proteasome-dependent protein turnover, not merely as a general toxicity reagent. This workflow connects RIPK3 stabilization, viral immune evasion, and quantitative proteasome assays while emphasizing controls, timing, and compound stability.

• Sunitinib Workflows for RTK and RCC Research

  2026-09-09

  Build reproducible Sunitinib assays for VEGFR-driven angiogenesis, renal cell carcinoma growth, apoptosis, and resistance studies. A practical workflow also shows how ferroptosis-focused combination experiments can reveal why some RCC models become more sensitive to RTK inhibition.

• Lactate Workflows for Metabolic–Immune Research

  2026-09-08

  Build reproducible L-lactate experiments that separate glycolytic output from lactate-driven signaling in cells, tissues, and tumor–immune models. This workflow combines compartment-aware sampling, controlled dosing, and mechanistic validation around the NAT1–ENO1–lactate–PD-L1 axis.

8594 records 4/573 page Previous Next 12345 下5页 Last page